Study of a new treatment for KRAS G12D cancers
Part of Cancer, Digestive system, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced non-small cell lung, colorectal, pancreatic, endometrial, or another solid tumor that has spread or cannot be removed by surgery.
- Your tumor has a specific change in the KRAS gene called G12D, and you have a particular immune system marker (HLA-C*08:02, HLA-A*11:01, or HLA-A*11:02).
- You have tried at least one standard treatment for your cancer, and no more standard options are available.
- You are in generally good health (ECOG score 0-1) and have at least one measurable tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (TCR-T) designed to attack cancer cells with a specific KRAS mutation. It may be an option for people with advanced solid tumors who have run out of standard treatments.
This trial tests a new immune cell therapy (called RE002 T cells) for people with advanced solid tumors that have a specific KRAS G12V mutation and a certain HLA type. The therapy is designed to target and attack cancer cells that carry this mutation.
This study tests a new treatment for people with advanced solid tumors that have a specific genetic change called KRAS G12V. The treatment is designed to help the immune system attack cancer cells with this mutation, and the study aims to see if it is safe and effective.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.